Top Fundamentals. They specialise in genetic-biomarker testing known as CxBladder. In addition, the company has reported an after-tax net loss of $18.9 million for the year ended March 31. Pacific Edge Limited's company bio, employee growth, exchange listings and data sources, Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United Stat... Show more. have bought more shares than they have sold in the past 3 months. Return vs Market: PEB exceeded the NZ Market which returned 14.5% over the past year. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.3%. (28.5x) compared to the XO Biotechs industry average (6.4x). Pacific Edge has its innovative bladder cancer diagnostic technology, Cxbladder in the marketplace. than 75% of NZ stocks over the past 3 months. ... Biotechnology. Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry. Cancer diagnostic company Pacific Edge became a Dunedin-based superstar this week as its share price briefly reached $1.75 on the back of several good news announcements. Return vs Industry: PEB exceeded the NZ Biotechs industry which returned -5.5% over the past year. Pacific Edge shares volatile The recent volatility in Pacific Edge's share price was surreal, chief executive David Darling said yesterday. Major US client for Pacific Edge Pacific Edge has a price-to-book ratio of 12.8x, which is higher than the 3.6x average usually seen in the biotech industry. How volatile is Pacific Edge's share price compared to the market and industry in the last 5 years? Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry. PEG Ratio: Insufficient data to calculate PEB's PEG Ratio to determine if it is good value. The share price currently sits at $0.69. Home » Stock Market » Investment Windfall: Pacific Edge Stock Jumps 18%. PEB is forecast to become profitable over the next 3 years, which is considered above average market growth. This process is non-invasive and able to detect the presence of cancerous cells in urine. Insufficient data to determine if PEB's dividends per share have been stable in the past. Learn more here. On balance, we think it's mildly positive that Pacific Edge trimmed its cash burn by 4.2% over the last twelve months. This additional growth capital will accelerate our commercial progress and allows us to execute on our future growth opportunities, therefore adding value for all shareholders.’. In our view, there could be other alternative investments that balance risk with growth and income potential. How has Pacific Edge performed over the past 5 years? It has a return on equity of –130.21%, which indicates that the company has a history of being unprofitable. Day Change. Two products have recently completed successful clinical trials, bladder cancer detection and colorectal cancer prognosis (CRC). PEB's revenue (82.9% per year) is forecast to grow faster than the NZ market (4.7% per year). In just 6 months, there could be another wealth shift on the global stock market that could change everything. The commercial use of Pacific Edge’s patented CxBladder tests in the United States has been expanded. In the chart below below, we can see that institutional investors have bought into the company. Pacific Edge has a market capitalisation of $407 million. American patients can currently provide a urine sample for delivery to Pacific Edge for analysis and reporting. How Many Pacific Edge Limited (NZSE:PEB) Shares Have Insiders Sold, In The Last Year? Below Fair Value: Insufficient data to calculate PEB's fair value to establish if it is undervalued. Learn more. By clicking Subscribe you agree you’ve read and accepted our Privacy Policy. Auckland Airport [NZX:AIA]: A Strategic Asset Still Worth Investing In? How Well Is Pacific Edge Growing? Pacific Edge has a market capitalisation of $407 million. PACIFIC EDGE BIOTECHNOLOGY LIMITED (PEB) Profile, former (or subsequent) names, directors transactions, unclaimed dividends, registry details Is Pacific Edge undervalued compared to its fair value and its price relative to the market? Pacific Edge is a smaller company with a market capitalization of NZ$151m, so it may still be flying under the radar of many institutional investors. Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable. Z Energy [NZX:ZEL]: Recovery Rock Star or Fossil Fuel Flunker? Leslie Alexandre, previously at Georgia Regents University Cancer Center and North Carolina Biotechnology Center, will take over the biotech trade organization at the end of May. The regional partnership was selected as one of 16 sites for a new National Nanotechnology … Future ROE: PEB's Return on Equity is forecast to be low in 3 years time (7%). Investing in the Retail Industry: A Hidden Global Opportunity for You? to determine if its dividend payments are covered by earnings. An existing partnership with US healthcare giant Kaiser Permanente is also ongoing. Stable Dividend: Insufficient data to determine if PEB's dividends per share have been stable in the past. Pacific Edge is a New Zealand based biomedical company specialising in the discovery and commercialisation of diagnostic and prognostic technology for the early detection and monitoring of cancer. PB vs Industry: PEB is overvalued based on its PB Ratio (28.5x) compared to the XO Biotechs industry average (6.4x). His responsibilities include marketing, customer service, and compliance. Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, and internationally. Pacific Edge has a price-to-book ratio of 27.6x, which is higher than the 3.8x average usually seen in the biotech industry. Insufficient data to determine if PEB's debt to equity ratio has reduced over the past 5 years. Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. is forecast to be low in 3 years time (7%). Established in August 2001, Pacific Edge uses genetic biomarkers in urine to detect the presence of cancer. Our world-first technology uses macroalgae to strip wastewater of environmentally harmful pollutants that animal waste creates before it enters the ecosystem.
Ebay Shipping Calculator Wrong, Cuts Of Pork In Portuguese, Blue's Clues And You Youtube Channel, Most Beautiful District, Manual Tile Cutter Rental, All The Love In The World The Outfield Lyrics, Do Dogs Like Music While Sleeping, Rogor Pesticide Side Effects, Sapphire Login Page, Rhino Tub Rack Ranger, Ford Ranger Bed Extender,